StockNews.com Upgrades Pulse Biosciences (NASDAQ:PLSE) to Sell

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research note released on Thursday.

Pulse Biosciences Trading Up 10.3 %

Shares of PLSE stock opened at $19.63 on Thursday. The business’s 50 day moving average is $18.06 and its two-hundred day moving average is $16.95. Pulse Biosciences has a twelve month low of $6.59 and a twelve month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the previous year, the firm posted ($0.19) EPS.

Insider Buying and Selling

In related news, Director Robert W. Duggan bought 55,256 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were bought at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the transaction, the director now owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Burke Thomas Barrett sold 50,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the transaction, the chief executive officer now owns 63,172 shares of the company’s stock, valued at $1,100,456.24. This represents a 44.18 % decrease in their position. The disclosure for this sale can be found here. 71.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers increased its stake in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after purchasing an additional 1,608 shares in the last quarter. Quest Partners LLC acquired a new stake in Pulse Biosciences in the second quarter valued at $91,000. Bank of New York Mellon Corp increased its position in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after buying an additional 9,639 shares in the last quarter. Creative Planning raised its stake in shares of Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after buying an additional 11,667 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new stake in shares of Pulse Biosciences in the 3rd quarter worth about $378,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.